Clinical characteristics of transgender patients with breast cancer: a single institution experience.

IF 4.8 2区医学 Q1 ONCOLOGY

Oncologist Pub Date : 2025-05-08 DOI:10.1093/oncolo/oyaf087

Ethan Ravetch, Nithya Krishnamurthy, Christina Weltz, Joshua D Safer

{"title":"Clinical characteristics of transgender patients with breast cancer: a single institution experience.","authors":"Ethan Ravetch, Nithya Krishnamurthy, Christina Weltz, Joshua D Safer","doi":"10.1093/oncolo/oyaf087","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer presents unique complexities for transgender individuals. This retrospective study characterized breast cancers in 14 transgender and nonbinary patients treated at a specialized transgender health center from 2016 to 2023. Patients with a median age of 53 (31-65 years) were identified using international classification of disease-10 codes. Most (86%) were aged 40 or older and eligible for screening mammography. The cohort included 6 trans men, 7 trans women, and one genderqueer individual. Diagnoses included ductal carcinoma in situ (36%), lobular carcinoma in situ (7%), stage 1 (29%), stage 2 (21%), and breast implant-associated anaplastic large cell lymphoma (7%). Screening mammography diagnosed 29%, 43% presented with a mass, and 29% were detected during pre-surgical imaging. Half had estrogen-based gender-affirming hormone therapy (GAHT) and half testosterone-based, with mean GAHT durations of 16.6 years. Biomarker profiles revealed 67% estrogen receptor (ER)-positive and 33% ER-negative cancers. This study highlights underutilized screening mammography and diverse cancer subtypes in this underserved population.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 5","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107534/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/oncolo/oyaf087","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Breast cancer presents unique complexities for transgender individuals. This retrospective study characterized breast cancers in 14 transgender and nonbinary patients treated at a specialized transgender health center from 2016 to 2023. Patients with a median age of 53 (31-65 years) were identified using international classification of disease-10 codes. Most (86%) were aged 40 or older and eligible for screening mammography. The cohort included 6 trans men, 7 trans women, and one genderqueer individual. Diagnoses included ductal carcinoma in situ (36%), lobular carcinoma in situ (7%), stage 1 (29%), stage 2 (21%), and breast implant-associated anaplastic large cell lymphoma (7%). Screening mammography diagnosed 29%, 43% presented with a mass, and 29% were detected during pre-surgical imaging. Half had estrogen-based gender-affirming hormone therapy (GAHT) and half testosterone-based, with mean GAHT durations of 16.6 years. Biomarker profiles revealed 67% estrogen receptor (ER)-positive and 33% ER-negative cancers. This study highlights underutilized screening mammography and diverse cancer subtypes in this underserved population.

查看原文本刊更多论文

跨性别乳腺癌患者的临床特征：单一机构经验。

乳腺癌对变性人来说具有独特的复杂性。这项回顾性研究分析了2016年至2023年在一家专门的跨性别健康中心接受治疗的14名跨性别和非二元性别患者的乳腺癌。患者中位年龄为53岁（31-65岁），采用国际疾病分类-10代码进行鉴定。大多数（86%）年龄在40岁或以上，符合筛查性乳房x光检查的条件。该队列包括6名跨性别男性、7名跨性别女性和1名性别酷儿个体。诊断包括导管原位癌（36%）、小叶原位癌（7%）、1期（29%）、2期（21%）和乳房植入物相关间变性大细胞淋巴瘤（7%）。筛查乳房x光检查诊断出29%，43%出现肿块，29%在术前影像学检查中被发现。一半接受基于雌激素的性别确认激素治疗（GAHT），一半接受基于睾酮的治疗，平均GAHT持续时间为16.6年。生物标志物显示67%的雌激素受体（ER）阳性和33%的ER阴性癌症。这项研究强调了在这一服务不足的人群中未充分利用的乳房x光筛查和不同的癌症亚型。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncologist 医学-肿瘤学

CiteScore

10.40

自引率

3.40%

发文量

309

审稿时长

3-8 weeks

期刊介绍： The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.